Is Grifols, S.A. (GRFS) a Buy, Sell, or Hold?
Grifols, S.A.
NASDAQ:GRFS
$7.21 USD
$0.19 (2.71%)
- Volume
- 582.89K
- Average Volume
- 692.69K
- Market Capitalization
- $6.1B
- P/E Ratio
- 14.79
- Dividend Yield
- 0.91%
- Price Target
- $
- Year High
- $11.14
- Year Low
- $6.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.31
- Current Ratio
- $2.47
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jose Ignacio Abia Buenache |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | GRFS |
| CUSIP | 398438408 |
| CIK | 0001438569 |
| Web | https://www.grifols.com |
| Phone | 34 93 571 02 21 |
| Currency | USD |
| Employees | 23833 |
| Country | ES |
Liquidity
| Debt-to-Equity Ratio | 1.77 |
| Payout Ratio | 0.31 |
| Current Ratio | 2.47 |
| Quick Ratio | 0.85 |
| Cash Ratio | 0.33 |
Sales & Book Value
| Annual Sales | $7.23B |
| Price / Sales | 0.83 |
| Cash Flow | 1.11 |
| Price / Cash Flow | 8.15 |
| Price / Book | 1.12 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.57 |
| Trailing P/E Ratio | 14.79 |
| PEG Ratio | 0.13 |
| P/E Growth | 0.13 |
| Net Income | $386.13M |
| Net Margin | 5.58% |
| Pretax Margin | 8.23% |
| Return on Equity | 7.88% |
| Return on Assets | 2.07% |
Financials Score
| AltmanZ Score | 1.01 |
| Piotroski Score | 5.00 |
| Working Capital | 3.13B |
| Total Assets | 20.1B |
| Ebit | 1.21B |
| Market Cap | 5.19B |
| Total Liabilities | 12.24B |
Poll Results
About Grifols, S.A. (NASDAQ:GRFS) Stock
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic product ... s that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
2026-07-03 10:49:07
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
2026-06-15 08:00:00
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.
Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst
2026-06-04 07:18:30
Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader with global scale and supply security advantages. GRFS trades at a significant valuation discount—forward P/E of 8.42x and price/cash flow of 4.76x—despite robust EBITDA, margin expansion, and improving free cash flow. Recent refinancing pushes major debt maturities to 2028; management guides for 2026 EBITDA margins of at least 25% and €500–€575 million free cash flow pre-dividends.
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
2026-05-09 15:31:13
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Grifols, S.A. (GRFS) stock price?
-
Grifols, S.A.(NASDAQ:GRFS) stock price is $7.21 in the last trading session. During the trading session, GRFS stock reached the peak price of $11.14 while $6.96 was the lowest point it dropped to. The percentage change in GRFS stock occurred in the recent session was 2.71% while the dollar amount for the price change in GRFS stock was $0.19.
-
GRFS's industry and sector of operation?
-
The NASDAQ listed GRFS is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of GRFS?
-
Enrique de la Torre | Chief Compliance Officer
Daniel Segarra | Head of Investor Relations & Sustainability and Vice President
Daniel Fleta Coit | Chief Industrial Services Officer
Camille Alpi | Chief Human Resources & Talent Officer
David Ian Bell | Chief Corporate Affairs & Legal Officer -
How many employees does GRFS have?
-
Number of GRFS employees currently stands at 23833. GRFS operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.
-
Link for GRFS official website?
-
Official Website of GRFS is: https://www.grifols.com
-
How do I contact GRFS?
-
GRFS could be contacted at phone #34 93 571 02 21 and can also be accessed through its website. GRFS operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.
-
How many shares of GRFS are traded daily?
-
The average number of GRFS shares traded daily for last 3 months was 692.69K.
-
What is the market cap of GRFS currently?
-
The market value of GRFS currently stands at $6.1B with its latest stock price at $7.21